Estuardo Aguilar-Cordova,
M.D., inf., Ph.D.

Dr. Estuardo Aguilar-Cordova is a Founder of Advantagene. He has more than 30 years of experience in the fields of biotherapeutics, cancer research and drug development, including serving as principal or co-investigator in more than 25 clinical trials ranging from Phase I to Phase III.

Dr. Aguilar-Cordova held academic positions for nearly two decades. He was deputy director of the Harvard Gene Therapy Initiative at Harvard Medical School in Boston and was a faculty member in Pediatrics, Hematology-Oncology at Baylor College of Medicine in Houston. He has served on national oversight committees, including roles as chairman and member of the NIH Recombinant Advisory Committee (RAC), as a consultant to the FDA Biological Response Modifiers Advisory Committee (BRMAC), and as a member of the Vaccine and Related Products Advisory Committee (VRPAC). Dr. Aguilar-Cordova has also held other appointments including president of the Latin American Gene Therapy Society.

Dr. Aguilar-Cordova has published more than 80 peer-reviewed scientific publications and book chapters, is on the editorial board of various professional journals and is an inventor on several patent applications.

A native of Guatemala, he completed his undergraduate studies in Biology at California State University, Bakersfield; Medicine, at Universidad Francisco Marroquín in Guatemala City; and Ph.D. in Molecular Genetics at the University of California at Davis.